NantHealth (DB:NEL0) - Prezzo delle azioni, notizie e analisi

NEL0 Panoramica delle azioni

Operates as a healthcare IT company in the United States, Canada, and the United Kingdom. Maggiori dettagli

NEL0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Analisi del rischio

Patrimonio netto negativo

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Le azioni sono altamente illiquide

Non ha una capitalizzazione di mercato significativa ( €13M )

NantHealth, Inc. Concorrenti

MeVis Medical Solutions

XTRA:M3V

€44.4m

DocCheck

XTRA:AJ91

€41.4m

CompuGroup Medical SE KGaA

XTRA:COP

€786.4m

Geratherm Medical

XTRA:GME

€21.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per NantHealth
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.26
Massimo di 52 settimane	US$5.17
Minimo di 52 settimane	US$0.20
Beta	1.64
1Variazione di 1 mese	0%
Variazione a 3 mesi	0%
Variazione di 1 anno	-93.60%
3Variazione a 3 anni	-99.06%
Variazione a 5 anni	-98.24%
Variazione dall'IPO	-99.86%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	NEL0	DE Healthcare Services	DE Mercato
7D	0%	2.3%	0.8%
1Y	-93.6%	-31.3%	9.1%

Ritorno vs Industria: NEL0 ha avuto una performance inferiore rispetto al German Healthcare Services che ha registrato un rendimento -31.3 % nell'ultimo anno.

Rendimento vs Mercato: NEL0 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 9.1 % nell'ultimo anno.

Volatilità dei prezzi

Is NEL0's price volatile compared to industry and market?
NEL0 volatility
NEL0 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di NEL0 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di NEL0 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2010	373	Rao Naseem	nanthealth.com

NantHealth, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di NantHealth con la sua capitalizzazione di mercato?
NEL0 statistiche fondamentali
Capitalizzazione di mercato	€11.54m
Guadagni(TTM)	-€63.09m
Ricavi(TTM)	€62.54m

0.2x

Rapporto P/S

-0.2x

Rapporto P/E

NEL0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NEL0 Conto economico (TTM)
Ricavi	US$68.44m
Costo del fatturato	US$23.74m
Profitto lordo	US$44.69m
Altre spese	US$113.74m
Guadagni	-US$69.04m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.51
Margine lordo	65.31%
Margine di profitto netto	-100.89%
Rapporto debito/patrimonio netto	-111.3%

Come si è comportato NEL0 nel lungo periodo?

Vedi performance storica e confronto

NEL0 Panoramica delle azioni

Analisi del rischio

NantHealth, Inc. Concorrenti

XTRA:M3V

€44.4m

XTRA:AJ91

€41.4m

XTRA:COP

€786.4m

XTRA:GME

€21.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2021)

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought €4.2m worth of stock

Founder recently bought €4.2m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Chief Operating Officer recently sold €249k worth of stock

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue misses expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €3.88

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: €3.41

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Revenue beats expectations

Third quarter 2020 earnings released: US$0.099 loss per share

New 90-day low: €1.75

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low - €2.23

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

NantHealth, Inc. Riepilogo dei fondamenti